Health Care & Life Sciences » Pharmaceuticals | Pacira Pharmaceuticals Inc.

Pacira Pharmaceuticals Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
73,785.00
158,167.00
158,965.00
172,597.00
311,347.00
383,454
Total Accounts Receivable
14,590.00
22,366.00
25,855.00
29,937.00
31,658.00
38,000
Inventories
15,557.00
29,263.00
61,645.00
31,278.00
41,411.00
48,569
Other Current Assets
2,819.00
4,461.00
6,117.00
9,277.00
6,694.00
7,946
Total Current Assets
106,751.00
214,257.00
252,582.00
243,089.00
391,110.00
477,969
Net Property, Plant & Equipment
48,182.00
60,632.00
90,324.00
101,016.00
107,046.00
108,670
Total Investments and Advances
-
24,431.00
13,462.00
-
74,193.00
40,017
Intangible Assets
11,485.00
24,164.00
30,961.00
46,737.00
55,197.00
62,040
Other Assets
3,402.00
2,588.00
406.00
624.00
825.00
657
Total Assets
169,820.00
326,072.00
387,735.00
391,466.00
628,371.00
689,353
ST Debt & Current Portion LT Debt
99,981.00
103,376.00
104,040.00
-
324.00
Accounts Payable
3,069.00
6,758.00
8,739.00
7,511.00
14,658.00
Income Tax Payable
-
139.00
208.00
66.00
76.00
Other Current Liabilities
18,893.00
29,737.00
36,801.00
37,261.00
41,159.00
Total Current Liabilities
121,943.00
140,010.00
149,788.00
44,838.00
56,217.00
Long-Term Debt
226.00
-
-
108,738.00
276,173.00
Provision for Risks & Charges
-
-
600.00
500.00
1,500.00
Other Liabilities
6,402.00
14,917.00
18,955.00
18,414.00
14,998.00
Total Liabilities
128,571.00
154,927.00
169,343.00
172,490.00
348,888.00
Common Equity (Total)
41,249.00
171,145.00
218,392.00
218,976.00
279,483.00
Total Shareholders' Equity
41,249.00
171,145.00
218,392.00
218,976.00
279,483.00
Total Equity
41,249.00
171,145.00
218,392.00
218,976.00
279,483.00
Liabilities & Shareholders' Equity
169,820.00
326,072.00
387,735.00
391,466.00
628,371.00

About Pacira Pharmaceuticals

View Profile
Address
5 Sylvan Way
Parsippany New Jersey 07054
United States
Employees -
Website http://www.pacira.com
Updated 07/08/2019
Pacira Pharmaceuticals, Inc. is a holding company, which engages in the development, commercialization, and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients. Its flagship product, EXPAREL, redefines pain management after surgery as an opioid-free alternative indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The company was founded in December 2006 and is headquartered in Parsippany, NJ.